The history of the SI "Institute of Pharmacology and Toxicology of NAMS of Ukraine" which is conducted from the Kyiv Scientific Sanitary and Chemical Institute founded in 1934 to the Institute's entry into the scientific environment of the NAMS of Ukraine has absorbed the successive activities of generations of scientists, which relate to the development of means of chemical protection, antidotes and medicines for the clinical translation of pharmacotherapy’s technologies.
In recent decades, the basis of the Institute's activity have been fundamental and applied studies in the field of pharmacology and drug toxicology of potential means for treatment of cardiovascular, oncologic and ophthalmologic diseases, metabolic disorders, antimicrobial agents and means of pharmacological correction of pain and inflammation.
Developing the concepts of channelopathies, it was shown that the generation of reactive oxygen causes a inhibition of the potassium currents of the smooth muscle cells of the animal aorta due to the dysfunction of the ВКСа channels. Based on a combination of methods in silico, rational design, prognostic synthesis and pharmacological screening, the algorithm for creating substances with predicted anti-inflammatory and analgesic effects was optimized. For the first time, the role of the differentiation of the transcriptional activity of Quorum sensing genes for the antibiofilm activity of the adamantane derivatives was established. The effect of antiglycemic correction on negative changes in male reproductive function and the development of offspring due to the induced metabolic syndrome have been determined. The benefits and caveats regarding the use of various classes of known drugs against the background of comorbid pathology of inflammatory genesis associated with hypertension and oncology are substantiated.
In recent decades, the following original drugs, including Pyrodazole, Adamicrine, Dimeodipine, Fludinate,Amizon, Chlofiden, Broteofin, Mebifon, Antral, Vitam, Esmin and innovative liposomal products Lipin, Lioliv, Lipoflavon, Lipochrome and Lipoprost have been proposed for introduction and introduced into medical practice in cardiology, oncology, hepatology, nephrology, pediatrics and ophthalmology.
In response to today's challenges, new information has been obtained on the effect of known antimicrobial drugs on biofilm formation and virulence of pathogenic microorganisms for the development of rational schemes of pharmacotherapy of injuries with an infectious component; researches regarding the impact of post-traumatic stress disorders on male reproductive function have been initiated to substantiate ways of pharmacological correction of the consequences of the demographic crisis, the application of innovative liposomal agents for the treatment of inflammatory lesions with a fatal ARDS component (combat and catastrophic injuries, severe consequences of COVID) has been proposed.
Non-clinical aspects of drug development are the subject of a significant amount of research projects under state grants and on request of the pharmindustry and medical institutions, the results of which were used in registration, organization of production, quality control and medical use more than 270 drugs annually. The methodology of GLP and modern statistical algorithms are used in the process of implementation of these projects.
The relevance and novelty of the results of the Institute's activities over 30 years are confirmed by the status of their published works in specialized scientific publications: 30 monographs and textbooks, more than 2500 articles and abstracts of reports and 114 patents (3261 publications and patent abroad).
The Institute is the founder of the Association of Pharmacologists of Ukraine and a collective member of the International Union of Theoretical and Clinical Pharmacology (IUPHAR). Scientists of the Institute cooperate with scientific institutions of